Patents Assigned to ImmuPharma (France) SA
  • Patent number: 10213482
    Abstract: The present invention relates to a peptide, or a salt thereof, comprising or consisting of the amino acid sequence IHMVYSKRSGKPRGYAFIEY, comprising one or more post-translational modifications, for the treatment, prevention or amelioration of a hyper autophagy-related autoimmune disease or disorder.
    Type: Grant
    Filed: December 11, 2015
    Date of Patent: February 26, 2019
    Assignees: ImmuPharma France SA, Centre National De La Recherche Scientifique
    Inventors: Sylviane Muller, Robert H. Zimmer, Jean-Paul Briand
  • Patent number: 9657072
    Abstract: The present invention relates to a peptide, or a salt thereof, comprising or consisting of the amino acid sequence IHMVYSKRSGKPRGYAFIEY, comprising one or more post-translational modifications.
    Type: Grant
    Filed: December 5, 2014
    Date of Patent: May 23, 2017
    Assignees: Centre National De La Recherche Scientifique, Immupharma France SA
    Inventors: Sylviane Muller, Jean-Paul Briand, Robert H. Zimmer
  • Publication number: 20150111835
    Abstract: The present invention relates to a peptide, or a salt thereof, comprising or consisting of the amino acid sequence IHMVYSKRSGKPRGYAFIEY, comprising one or more post-translational modifications.
    Type: Application
    Filed: December 5, 2014
    Publication date: April 23, 2015
    Applicants: IMMUPHARMA FRANCE SA, CENTRE NATIONAL DE LA RECHERECHE SCIENTIFIQUE
    Inventors: Sylviane Muller, Jean-Paul Briand, Robert H. Zimmer
  • Patent number: 8138145
    Abstract: The present invention relates to compositions and methods for producing therapeutic oligomeric compounds. In one aspect the invention relates to methods for administering the oligomeric compounds for the treatment and prevention of disease, for example, a fungal infection, bacterial infection, or cancer, in a mammal. In particular, the invention relates to medicaments comprising various novel oligomeric compounds and pharmaceutically acceptable salts thereof. The compounds of the invention may optionally be administered with at least one of a pharmaceutically acceptable excipient, pharmacologically active agent or a combination thereof.
    Type: Grant
    Filed: February 18, 2010
    Date of Patent: March 20, 2012
    Assignees: Centre National de la Recherche Scientifique (SNRS), ImmuPharma France SA
    Inventors: Aude Violette, Jean-Paul Briand, Robert H. Zimmer, Gilles Guichard
  • Publication number: 20100298206
    Abstract: The present invention relates to compositions and methods for producing therapeutic oligomeric compounds. In one aspect the invention relates to methods for administering the oligomeric compounds for the treatment and prevention of disease, for example, a fungal infection, bacterial infection, or cancer, in a mammal. In particular, the invention relates to medicaments comprising various novel oligomeric compounds and pharmaceutically acceptable salts thereof. The compounds of the invention may optionally be administered with at least one of a pharmaceutically acceptable excipient, pharmacologically active agent or a combination thereof.
    Type: Application
    Filed: February 18, 2010
    Publication date: November 25, 2010
    Applicants: Centre National de la Recherche Scientifique (CNRS), I.B.M.C., ImmuPharma France SA, Technopole
    Inventors: Aude Violette, Jean-Paul Briand, Robert H. Zimmer, Gilles Guichard
  • Publication number: 20100291199
    Abstract: The present invention relates to various novel substituted dipeptide derived nitrogen-containing heterocyclic compounds, their pharmaceutically acceptable salt derivatives, and their methods of use. In one aspect the present invention relates to compositions and methods for the treatment and prevention of disease in a mammal comprising administering the compounds of the invention in a pharmaceutically acceptable form to a mammal. In particular, the invention relates to medicaments comprising various novel substituted dipeptide derived nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salt derivatives and methods for administration to a mammal for the treatment and prevention of malarial diseases. The compounds of the invention may optionally be administered with at least one pharmaceutically acceptable excipient, another biologically active agent or a combination thereof.
    Type: Application
    Filed: July 23, 2010
    Publication date: November 18, 2010
    Applicants: Centre National de la Recherche Scientifique (CNRS), ImmuPharma France SA
    Inventors: Gilles Guichard, Gersande Lena, Eliette Lallemand, Laurent Renia
  • Patent number: 7777030
    Abstract: The present invention relates to various novel substituted dipeptide derived nitrogen-containing heterocyclic compounds, their pharmaceutically acceptable salt derivatives, and their methods of use. In one aspect the present invention relates to compositions and methods for the treatment and prevention of disease in a mammal comprising administering the compounds of the invention in a pharmaceutically acceptable form to a mammal. In particular, the invention relates to medicaments comprising various novel substituted dipeptide derived nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salt derivatives and methods for administration to a mammal for the treatment and prevention of malarial diseases. The compounds of the invention may optionally be administered with at least one pharmaceutically acceptable excipient, another biologically active agent or a combination thereof.
    Type: Grant
    Filed: December 22, 2006
    Date of Patent: August 17, 2010
    Assignees: Centre National de la Recherge Scientifique (CNRS), ImmuPharma France SA
    Inventors: Gilles Guichard, Gersande Lena, Eliette Lallemand, Laurent Renia
  • Patent number: 7691807
    Abstract: The present invention relates to compositions and methods for producing therapeutic oligomeric compounds. In one aspect the invention relates to methods for administering the oligomeric compounds for the treatment and prevention of disease, for example, a fungal infection, bacterial infection, or cancer, in a mammal. In particular, the invention relates to medicaments comprising various novel oligomeric compounds and pharmaceutically acceptable salts thereof. The compounds of the invention may optionally be administered with at least one of a pharmaceutically acceptable excipient, pharmacologically active agent or a combination thereof.
    Type: Grant
    Filed: March 17, 2006
    Date of Patent: April 6, 2010
    Assignees: Centre National de la Recherche Scientifique (CNRS), ImmuPharma France SA
    Inventors: Aude Violette, Jean-Paul Briand, Robert Zimmer, Gilles Guichard
  • Patent number: 7186739
    Abstract: A carbamate compound is disclosed.
    Type: Grant
    Filed: March 11, 2005
    Date of Patent: March 6, 2007
    Assignee: ImmuPharma (France) SA
    Inventors: Gilles Guichard, Marie-Christine Galas-Rodriguez, legal representative, Pierre Rodriguez, legal representative, Elisa Rodriguez, legal representative, Romain Rodriguez, legal representative, Vincent Semetey, Jean-Paul Briand, Marc Rodriguez, deceased
  • Patent number: 7186828
    Abstract: A method for preparing cyclic urea compounds from at least an activated carbamic acid derivative containing an unprotected primary or secondary amine function, includes a cyclization step which consists in a reaction between the primary or secondary amine function and the carbamic acid function of the carbamic acid derivative(s).
    Type: Grant
    Filed: June 13, 2001
    Date of Patent: March 6, 2007
    Assignee: ImmuPharma (France) SA
    Inventors: Gilles Guichard, Marie-Christine Galas-Rodriguez, legal representative, Pierre Rodriguez, legal representative, Elisa Rodriguez, legal representative, Romain Rodriguez, legal representative, Serge Plaue, Vincent Semetey, Arnaud-Pierre Schaffner, Jean-Paul Briand, Marc Rodriguez, deceased